Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Receives $33.47 Average Price Target from Analysts

Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLSGet Free Report) have received a consensus rating of “Hold” from the nineteen ratings firms that are currently covering the company, MarketBeat reports. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating, nine have issued a buy rating and one has issued a strong buy rating on the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $33.4706.

A number of analysts recently weighed in on the stock. Wells Fargo & Company assumed coverage on shares of Apellis Pharmaceuticals in a research note on Wednesday, October 15th. They issued an “overweight” rating and a $32.00 target price on the stock. The Goldman Sachs Group lowered shares of Apellis Pharmaceuticals from a “neutral” rating to a “sell” rating and lowered their target price for the stock from $26.00 to $18.00 in a report on Friday, September 26th. Wall Street Zen raised shares of Apellis Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, August 2nd. Morgan Stanley upped their target price on shares of Apellis Pharmaceuticals from $25.00 to $26.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 2nd. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Apellis Pharmaceuticals in a report on Wednesday, October 8th.

View Our Latest Analysis on APLS

Apellis Pharmaceuticals Stock Performance

NASDAQ APLS opened at $24.52 on Friday. The stock has a market cap of $3.10 billion, a P/E ratio of -13.47 and a beta of 0.69. The company’s 50-day simple moving average is $25.38 and its 200 day simple moving average is $21.16. Apellis Pharmaceuticals has a twelve month low of $16.10 and a twelve month high of $35.72. The company has a quick ratio of 3.16, a current ratio of 3.77 and a debt-to-equity ratio of 2.90.

Apellis Pharmaceuticals (NASDAQ:APLSGet Free Report) last posted its earnings results on Thursday, July 31st. The company reported ($0.33) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.11. The business had revenue of $171.39 million for the quarter, compared to analysts’ expectations of $187.91 million. Apellis Pharmaceuticals had a negative net margin of 30.24% and a negative return on equity of 116.09%. The firm’s revenue for the quarter was down 10.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.30) earnings per share. As a group, research analysts forecast that Apellis Pharmaceuticals will post -1.7 earnings per share for the current fiscal year.

Insider Transactions at Apellis Pharmaceuticals

In other news, Director A. Sinclair Dunlop sold 31,092 shares of the company’s stock in a transaction dated Friday, October 10th. The shares were sold at an average price of $23.72, for a total value of $737,502.24. Following the sale, the director owned 3,837 shares of the company’s stock, valued at approximately $91,013.64. This represents a 89.01% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Cedric Francois sold 49,963 shares of the company’s stock in a transaction dated Thursday, August 28th. The stock was sold at an average price of $28.39, for a total transaction of $1,418,449.57. Following the completion of the sale, the chief executive officer directly owned 307,946 shares in the company, valued at approximately $8,742,586.94. The trade was a 13.96% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 302,921 shares of company stock valued at $8,210,566. 6.80% of the stock is owned by insiders.

Institutional Investors Weigh In On Apellis Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Highland Capital Management LLC acquired a new stake in Apellis Pharmaceuticals in the 3rd quarter valued at about $1,135,000. Brighton Jones LLC increased its position in Apellis Pharmaceuticals by 16.2% in the 3rd quarter. Brighton Jones LLC now owns 19,214 shares of the company’s stock valued at $435,000 after acquiring an additional 2,675 shares in the last quarter. Voya Investment Management LLC increased its position in Apellis Pharmaceuticals by 14.8% in the 3rd quarter. Voya Investment Management LLC now owns 172,934 shares of the company’s stock valued at $3,913,000 after acquiring an additional 22,341 shares in the last quarter. Wedmont Private Capital acquired a new stake in Apellis Pharmaceuticals in the 3rd quarter valued at about $258,000. Finally, Osaic Holdings Inc. increased its position in Apellis Pharmaceuticals by 141.2% in the 2nd quarter. Osaic Holdings Inc. now owns 2,682 shares of the company’s stock valued at $47,000 after acquiring an additional 1,570 shares in the last quarter. Institutional investors and hedge funds own 96.29% of the company’s stock.

Apellis Pharmaceuticals Company Profile

(Get Free Report)

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).

Further Reading

Analyst Recommendations for Apellis Pharmaceuticals (NASDAQ:APLS)

Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.